WO2001012206A3 - Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen - Google Patents

Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen Download PDF

Info

Publication number
WO2001012206A3
WO2001012206A3 PCT/EP2000/007315 EP0007315W WO0112206A3 WO 2001012206 A3 WO2001012206 A3 WO 2001012206A3 EP 0007315 W EP0007315 W EP 0007315W WO 0112206 A3 WO0112206 A3 WO 0112206A3
Authority
WO
WIPO (PCT)
Prior art keywords
soy
aromatase inhibitors
positively influencing
substances
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/007315
Other languages
English (en)
French (fr)
Other versions
WO2001012206A2 (de
Inventor
Heinrich Wieland
Alfred Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7918298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001012206(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT00953113T priority Critical patent/ATE506986T1/de
Application filed by Individual filed Critical Individual
Priority to US10/049,968 priority patent/US8278291B1/en
Priority to JP2001516551A priority patent/JP2004502634A/ja
Priority to EP00953113A priority patent/EP1253966B1/de
Priority to MXPA02001547A priority patent/MXPA02001547A/es
Priority to CA2380940A priority patent/CA2380940C/en
Priority to AU65678/00A priority patent/AU6567800A/en
Priority to BRPI0013272-1B1A priority patent/BR0013272B1/pt
Priority to DE50016101T priority patent/DE50016101D1/de
Publication of WO2001012206A2 publication Critical patent/WO2001012206A2/de
Anticipated expiration legal-status Critical
Publication of WO2001012206A3 publication Critical patent/WO2001012206A3/de
Priority to US11/518,516 priority patent/US20070148123A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Die Erfindung beschreibt die Verwendung einer Substanz und/oder von Substanzen bzw. einer diese Substanz und/oder Substanzen enthaltenden Zusammensetzung, wobei diese Substanz und/oder diese Substanzen die Bildung und/oder die Wirkung von Östrogenen hemmt bzw. hemmen, zur Stabilisierung, zur Vermehrung und/oder zur Restaurierung von Kollagen. Als geeignete Substanzen dienen insbesondere Aromatase-Inhibitoren und/oder Anti-Östrogene, ggf. unter zusätzlicher Verwendung von 5-alpha-Reduktase-Inhibitoren.
PCT/EP2000/007315 1999-08-13 2000-07-28 Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen Ceased WO2001012206A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU65678/00A AU6567800A (en) 1999-08-13 2000-07-28 Substances and agents for positively influencing collagen
CA2380940A CA2380940C (en) 1999-08-13 2000-07-28 Substances and agents for positively influencing collagen
US10/049,968 US8278291B1 (en) 1999-08-13 2000-07-28 Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof
JP2001516551A JP2004502634A (ja) 2000-07-28 2000-07-28 コラーゲンにプラス方向に影響を与えるための基質および薬剤
EP00953113A EP1253966B1 (de) 1999-08-13 2000-07-28 Substanzen und mittel zur positiven beeinflussung von kollagen
MXPA02001547A MXPA02001547A (es) 1999-08-13 2000-07-28 Extractos de glicinas de soya e inhibidores de aromatasa para afectar positivamente colageno.
BRPI0013272-1B1A BR0013272B1 (pt) 1999-08-13 2000-07-28 Uso de um inibidor de aromatase esteroidal
AT00953113T ATE506986T1 (de) 1999-08-13 2000-07-28 Substanzen und mittel zur positiven beeinflussung von kollagen
DE50016101T DE50016101D1 (de) 1999-08-13 2000-07-28 Substanzen und mittel zur positiven beeinflussung von kollagen
US11/518,516 US20070148123A1 (en) 1999-08-13 2006-09-07 Substances and agents for positively influencing collagen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938421 1999-08-13
DE19938421.5 1999-08-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/518,516 Continuation US20070148123A1 (en) 1999-08-13 2006-09-07 Substances and agents for positively influencing collagen

Publications (2)

Publication Number Publication Date
WO2001012206A2 WO2001012206A2 (de) 2001-02-22
WO2001012206A3 true WO2001012206A3 (de) 2002-08-01

Family

ID=7918298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007315 Ceased WO2001012206A2 (de) 1999-08-13 2000-07-28 Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen

Country Status (9)

Country Link
US (2) US8278291B1 (de)
EP (1) EP1253966B1 (de)
AT (1) ATE506986T1 (de)
AU (1) AU6567800A (de)
BR (1) BR0013272B1 (de)
CA (1) CA2380940C (de)
DE (1) DE50016101D1 (de)
MX (1) MXPA02001547A (de)
WO (1) WO2001012206A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
IL161162A0 (en) * 2001-10-10 2004-08-31 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
AU2003213958A1 (en) * 2002-04-03 2003-10-13 Jencap Research Ltd. Female birth control method
US6866856B2 (en) * 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
FR2861293B1 (fr) * 2003-10-22 2008-10-17 Greenpharma Sas Composition pour prevenir ou traiter des affections resultant d'un processus de mort cellulaire comprenant une lactone sesquiterpenique
DE102008012988A1 (de) 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Zusammensetzung und Verwendungen zur Beeinflussung des Haarwachstums
KR20140040690A (ko) * 2011-01-31 2014-04-03 루콜라스-엠.디. 리미티드 미용학적 용도
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338212A1 (de) * 1983-10-18 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1-methyl-androsta-1,4,6-trien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
WO1991000731A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5280035A (en) * 1989-08-04 1994-01-18 Schering Aktiengesellschaft Cycloalkylene azoles and their use as aromatase inhibitors
EP0684235A1 (de) * 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Azolyl-methyl-phenyl Derivate mit Aromatase inhibierender Aktivität
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
WO1996008231A1 (en) * 1994-09-14 1996-03-21 Central Sheffield University Hospitals Nhs Trust Control of hair growth
EP0776661A1 (de) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Kombinationspreparat eines Antistrogens und eines Glukokortikoids zur Behandlung von Autoimmunkrankheiten
WO1997036570A1 (de) * 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO1999062480A2 (fr) * 1998-05-29 1999-12-09 Parfums Christian Dior Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique
WO1999062459A2 (en) * 1998-06-05 1999-12-09 Nutramax Laboratories, Inc. Agents and methods for protection, treatment and repair of connective tissue

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5582832A (en) * 1995-06-06 1996-12-10 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Compositions for topical application to skin
EP0831769B2 (de) * 1995-06-07 2008-07-23 Lavin, Dr., Thomas N. Neue verwendungen von thyroidhormonen oder thyroidhormon aehnliche verbindungen
FR2779059B1 (fr) * 1998-05-29 2004-09-10 Guerlain Procede de traitement cosmetique pour lutter contre les effets du vieillissement cutane; nouvelles compositions cosmetiques pour sa mise en oeuvre
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US6071526A (en) * 1997-03-27 2000-06-06 S.W. Patentverwertungs Ges M.B. H. Cosmetic or cosmetic product for firming and soothing the skin in particular in the case of cellulite
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6461627B1 (en) * 1998-10-09 2002-10-08 Kabushiki Kaisha Yakult Honsha Skin preparations for external use
US20030211177A1 (en) * 2001-03-16 2003-11-13 Pineda Edwin H Method and composition for treatment and prevention of alopecia
US6920883B2 (en) * 2001-11-08 2005-07-26 Arthrocare Corporation Methods and apparatus for skin treatment

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338212A1 (de) * 1983-10-18 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1-methyl-androsta-1,4,6-trien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
WO1991000731A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5280035A (en) * 1989-08-04 1994-01-18 Schering Aktiengesellschaft Cycloalkylene azoles and their use as aromatase inhibitors
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
EP0776661A1 (de) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Kombinationspreparat eines Antistrogens und eines Glukokortikoids zur Behandlung von Autoimmunkrankheiten
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
EP0684235A1 (de) * 1994-05-27 1995-11-29 Mochida Pharmaceutical Co., Ltd. Azolyl-methyl-phenyl Derivate mit Aromatase inhibierender Aktivität
WO1996008231A1 (en) * 1994-09-14 1996-03-21 Central Sheffield University Hospitals Nhs Trust Control of hair growth
WO1997036570A1 (de) * 1996-03-29 1997-10-09 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite'
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO1999062480A2 (fr) * 1998-05-29 1999-12-09 Parfums Christian Dior Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique
WO1999062459A2 (en) * 1998-06-05 1999-12-09 Nutramax Laboratories, Inc. Agents and methods for protection, treatment and repair of connective tissue

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAIZU TANPAKUSHITSU KENKYU (1999), 2, 76-82 *
DATABASE CHEMAB [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORITA, KYOKO ET AL: "Effect of soybean isoflavone on bone metabolism", XP002161790, retrieved from STN Database accession no. 133:16833 *
THESEN: "formestane, a new aromatase inhibitor", PHARM. ZTG., vol. 141, no. 26, 1996, pages 32 - 40, XP000986872 *

Also Published As

Publication number Publication date
WO2001012206A2 (de) 2001-02-22
DE50016101D1 (de) 2011-06-09
BR0013272A (pt) 2002-04-23
EP1253966B1 (de) 2011-04-27
CA2380940A1 (en) 2001-02-22
US8278291B1 (en) 2012-10-02
ATE506986T1 (de) 2011-05-15
US20070148123A1 (en) 2007-06-28
AU6567800A (en) 2001-03-13
EP1253966A2 (de) 2002-11-06
BR0013272B1 (pt) 2013-10-15
CA2380940C (en) 2013-06-25
MXPA02001547A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AU4883096A (en) Nitric oxide synthase inhibitors
NO20030961L (no) Farmasöytiske preparater samt metode for behandling av hypogonadisme
NZ504432A (en) Use of lysophosphatidylethanolamine (18:1) and lysophosphatidylinositol to retard senescene and to enhance fruit ripening
AU1912197A (en) New inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them
WO2000028947A3 (fr) Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
CA2339670A1 (en) Double core tissue roll, dispenser and method
WO1999004752A3 (en) Methods for treating skin pigmentation
WO2001012206A3 (de) Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen
AU5283199A (en) Methods and composition for modulating flavonoid content
AU8853998A (en) Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
WO2002019982A3 (en) Cosmetic composition and method for reducing or preventing wrinkling
ES2176714T3 (es) Preparaciones desodorantes.
WO2002040016A8 (fr) Association d'inhibiteurs de calpaïne et de piegeurs des formes reactives de l'oxygene
AU2001296854A1 (en) Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity
EP0894494A3 (de) Zusammensetzungen für die Beschleunigung der Zellerneuerung
WO2002023985A3 (de) Wirkstoffkombinationen zum schutz von tierischen häuten und von leder
DE60044633D1 (de) Nicht therapeutische Verwendung von N-acetylglucosamin zur Hautschälung
AU5422899A (en) Dry extract of henna, method for producing said extract and use of the same
WO2003044277A3 (en) Method of deacidifying cellulose-based materials
HK1038700A1 (zh) 含有含羞草属酚类化合物的组合物
EP1236402A3 (de) Gemüseprodukte enthaltende Zusammensetzungen
AUPQ141899A0 (en) A method of and composition for preserving cellulosic material
IL174545A (en) Use of a two-component system for the preparation of a hair growth inhibiting composition
ZA982106B (en) Composition and method for topical application to skin, hair and nails.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000953113

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380940

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001547

Country of ref document: MX

Ref document number: 10049968

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000953113

Country of ref document: EP